Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.

By S. Davis, G. Donnan, M. Parsons, C. Levi, K. Butcher, A. Peeters, P. Barber, C. Bladin, D. Silva, Graham B Byrnes and 11 more. Lancet Neurology, 2008

1,092 citations recorded by the source corpus.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/803038ba6e1fa9afddebfb43487630cc2933ca36

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Alejandro Rabinstein
2. William Whiteley
3. G. Turc
4. D. Strbian

Citations in the corpus

• Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (2013, background): “umbra was associated with greater clinical response to reperfusion.(345,346,362,363) DEDAS (Dose Escalation of Desmoteplase for Acute Ischemic Stroke)(347) appeared to show intravenous des-”
• Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2016, methodology): “Thrombolytic Evaluation Trial (EPITHET) included 25 older patients.(46) The Third International Stroke Trial (IST-3) is the”
• European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke (2021, methodology): “Overall, 85 patients (86%) had PWI-DWI mismatch, but the trial did not demonstrate a clinical benefit of alteplase.(25) A pooled analysis of the EPITHET trial and an observational study showed that, among patients with PWIDWI mismatch within 3–6 h of symptom onset (101 patients), those treated with ”
• A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke (2013, neutral): “(%) 24 (20) 6 (18) 8 (24) 4 (13) 6 (30) 0.”